EPⓖT
Expanded Pre-Implantation Genomic Testing
EPⓖT is our flagship product, which expands genetic testing to include SNP panels evaluating the risk of single-gene disorders and evaluation of polygenic disorder risk.
EPⓖT allows the routine, inexpensive evaluation of hundreds of thousands of genetic variants, implementing a novel combination of embryo genotyping methods not previously combined into are productive genetics application. Among the genetic disorders whose phenotype risk can routinely be diagnosed by our genotyping methodology are:
Universal coverage of common single-gene disorders, such as Cystic Fibrosis, Thalassemia, BRCA, Sickle Cell Anemia, and Gaucher Disease Broad coverage of polygenic disorders, listed here.
The Genomic Prediction team comprises scientists at the forefront of polygenic trait prediction in human adults. Now, they are directing their proven methodology towards the human embryo.
As the first company to translate genomic predictors of polygenic disease risk into disease prevention through PGT, we set a world precedent for improved clinical care in IVF with our EPⓖT method.
Genomic prediction. Expanded.
Being able to detect chromosomal abnormalities, screen for single-gene disorders, and predict polygenic disease risks, EPⓖT is the most comprehensive genetic testing product ever created.
One test. Hundred of results.
Traditional preimplantation genetic diagnosis (PGD) procedures only test for a small selection of specific single-gene disorders at a time. By simultaneously screening for hundreds of single-gene disorders, EPⓖT provides the most extensive analysis of single-gene disorder risks available, allowing couples to make the most informed decision possible.
Polygenic disease prediction
EPⓖT is the first ever genetic test that allows for the risk evaluation of polygenic diseases — those genetic disorders which involve complex interactions of multiple genes, and which comprise the majority of known disorders with a genetic cause.
